Coherus Biosciences Inc (NASDAQ: CHRS) has a higher price-to-earnings ratio of 6.39x compared to its average ratio. CHRS has 36-month beta value of 0.90. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CHRS is 111.28M, and currently, short sellers hold a 28.59% ratio of that float. The average trading volume of CHRS on March 11, 2025 was 2.09M shares.
CHRS) stock’s latest price update
Coherus Biosciences Inc (NASDAQ: CHRS) has experienced a rise in its stock price by 7.10 compared to its previous closing price of 1.04. However, the company has seen a gain of 6.08% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-10 that Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers – Head of IR Denny Lanfear – CEO Paul Reider – CCO Sameer Goregaoker – SVP, Immuno-Oncology Marketing Theresa LaVallee – CDO Rosh Dias – CMO Bryan McMichael – CFO Conference Call Participants Srikripa Devarakonda – Truist Securities Yigal Nochomovitz – Citigroup Colleen Kusy – Baird Michael Nedelcovych – TD Cowen Brian Cheng – JPMorgan Douglas Tsao – H.C. Wainwright Operator Hello everyone and welcome to the Coherus Fourth Quarter Year Ending 2024 Financial Results Conference call.
CHRS’s Market Performance
CHRS’s stock has risen by 6.08% in the past week, with a monthly drop of -0.55% and a quarterly drop of -26.24%. The volatility ratio for the week is 10.00% while the volatility levels for the last 30 days are 7.94% for Coherus Biosciences Inc The simple moving average for the past 20 days is 1.93% for CHRS’s stock, with a -14.89% simple moving average for the past 200 days.
Analysts’ Opinion of CHRS
Many brokerage firms have already submitted their reports for CHRS stocks, with UBS repeating the rating for CHRS by listing it as a “Neutral.” The predicted price for CHRS in the upcoming period, according to UBS is $1.50 based on the research report published on August 16, 2024 of the previous year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CHRS reach a price target of $11. The rating they have provided for CHRS stocks is “Outperform” according to the report published on November 17th, 2023.
CHRS Trading at -10.44% from the 50-Day Moving Average
After a stumble in the market that brought CHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.81% of loss for the given period.
Volatility was left at 7.94%, however, over the last 30 days, the volatility rate increased by 10.00%, as shares sank -6.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.77% lower at present.
During the last 5 trading sessions, CHRS rose by +3.92%, which changed the moving average for the period of 200-days by -47.54% in comparison to the 20-day moving average, which settled at $1.0913. In addition, Coherus Biosciences Inc saw -19.29% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CHRS
Current profitability levels for the company are sitting at:
- -0.39 for the present operating margin
- 0.68 for the gross margin
The net margin for Coherus Biosciences Inc stands at 0.11. The total capital return value is set at -0.23.
Currently, EBITDA for the company is -111.67 million with net debt to EBITDA at 1.52. When we switch over and look at the enterprise to sales, we see a ratio of 0.0. The receivables turnover for the company is 2.4for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.06.
Conclusion
To put it simply, Coherus Biosciences Inc (CHRS) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
